During a press conference earlier today, March 19th, the Trump administration announced that chloroquine and hydroxychloroquine, among other drugs, are being approved by the Food and Drug Administration (FDA) to test as potential COVID-19 coronavirus treatments. This is not the first time these drugs have been mentionedas potential treatments for the viral illness: early testing of hydroxychloroquine in France showed promising results, with results indicating that 50% of patients that originally tested positive for the virus tested negative after just three days of treatment. However, though the results are still extremely unclear whether this is a viable solution, it may be critical to understand what this drug exactly is, and what is known about it already….(See link for article)



If you are a Lyme/MSIDS patient you are probably well aware of the drug Plaquenil.  You might even have taken it – I have.

Initially approved for malaria (although to this day they don’t know how it works),  it has become a “go to” drug for Lyme literate doctors treating Lyme/MSIDS due to its ability to inactivate the body’s immune response which decreases inflammation.

According to this press release https://med.umn.edu/news-events/covid-19-clinical-trial-launches-university-minnesota, the University of Minnesota is conducting a post-exposure treatment clinical trial for plaquenil for coronavirus COVID-19 disease.

Study parameters: